AG 4263
Alternative Names: AG-4263; AnergiX.RALatest Information Update: 15 Aug 2007
At a glance
- Originator Corixa Corporation
- Developer Corixa Corporation; Organon
- Class Antirheumatics
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 17 May 2005 No development reported - Phase-II for Rheumatoid arthritis in USA (IV)
- 30 Jul 2002 This compound is still in active development
- 24 Jan 2001 Corixa and Organon have amended their development agreement for AG 4263